{"name":"Medigene","slug":"medigene","ticker":"MDG1.DE","exchange":"XETRA","domain":"medigene.com","description":"Medigene is a biopharmaceutical company focused on cell therapy and immuno-oncology. The company has a marketed product, Veregen, and several pipeline candidates, including G207 and EndoTAG-1. Medigene is positioned to address various cancer indications with its innovative therapies.","hq":"Planegg/Martinsried, Germany","founded":0,"employees":"","ceo":"Selwyn Ho","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":18000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Veregen patent cliff ($10.4M at risk)","drug":"Veregen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EndoTAG-1 and Gemcitabine","genericName":"EndoTAG-1 and Gemcitabine","slug":"endotag-1-and-gemcitabine","indication":"Pancreatic cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Veregen","genericName":"Veregen","slug":"veregen","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"EndoTAG-1 and Gemcitabine","genericName":"EndoTAG-1 and Gemcitabine","slug":"endotag-1-and-gemcitabine","phase":"phase_2","mechanism":"EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis.","indications":["Pancreatic cancer"],"catalyst":""},{"name":"Veregen","genericName":"Veregen","slug":"veregen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2022-03-31","type":"earnings","headline":"Medigene Reports Full-Year 2021 Financial Results","summary":"Medigene reported its full-year 2021 financial results, with a net loss of €24.8 million.","drugName":"","sentiment":"neutral"},{"date":"2021-09-01","type":"deal","headline":"Medigene Signs Collaboration Agreement with Pfizer","summary":"Medigene entered into a collaboration agreement with Pfizer to develop and commercialize Medigene's T-cell receptor (TCR) therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE1SY05wS3pTYWVSU1l1SzJXZ2l2VWNWcUdPMGxIY2RCWnRfdEhPWFNmOW1BSmt0b3kxTC1xUk81M09hWi1QRFptQU9pRnJpUQ?oc=5","date":"2024-08-03","type":"pipeline","source":"eToro","summary":"Medigene AG (MDG1.DE) Stock Price, News & Analyst Forecast - eToro","headline":"Medigene AG (MDG1.DE) Stock Price, News & Analyst Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Veregen","drugSlug":"isotretinoin","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":10400000}],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Bristol-Myers Squibb","Roche Holding"],"therapeuticFocus":["Cell Therapy","Immuno-Oncology"],"financials":null,"yahoo":null}